At today's price, Cigna's stock implies roughly -2.8% to -1.0% annual free-cash-flow growth for the next ten years — essentially flat to declining — while the company's actual FCF grew 8.6% a year and revenue grew 12.1% a year over the past four years.
At its current price, CI implies roughly -2.8% annual FCF growth for the next 10 years (WACC 9%) — essentially flat or slightly declining.
Cigna's actual FCF growth has averaged +8.6% a year over the past 4 years; revenue grew +12.1% a year over the same span.
Required growth vs. historical growth
Required growth from the reverse DCF below. Historical CAGRs from 10-K FY2021 and FY2025 (FCF grew from $6.04B to $8.39B; revenue from $174.1B to $274.9B, both over 4 years).
Sensitivity: what if the discount rate moves?
| WACC | Required growth |
|---|---|
| 8% | -4.8% |
| 9% (base case) | -2.8% |
| 10% | -1.0% |
| 12% | +2.3% |
Across every discount rate tested, the required growth rate stays at or below the low single digits — nowhere close to Cigna's actual 8.6% FCF pace. This conclusion is unusually insensitive to the discount-rate assumption: no reasonable WACC choice pushes the required rate anywhere near what Cigna has actually delivered.
What would move this number
- Using 2025's standalone FCF ($8.39B) instead of trailing-twelve-month FCF ($9.11B) as the base nudges the required growth rate up slightly, from -2.8% to -1.7% at a 9% discount rate — health insurers' first-half cash flow tends to run seasonally weaker due to rising receivables, which the TTM figure smooths out.
- Narrowing net debt to only long-term debt (excluding short-term borrowings) would lower net debt further, pushing the required growth rate even lower — implying an even more pessimistic market view.
- Lowering the terminal growth rate from 2.5% to 2.0% would modestly raise the required growth rate, since the discounting effect would compound more heavily over the projection period.
Show your work
Inputs, sources, model assumptions, and the calculation
- Share price$276.08 — stockanalysis.com, Aug 31, 2026 close
- Shares outstanding264,240,486 — 10-Q Q2 FY2026 cover page, Jul 24, 2026
- Market cap$72.95B — price × shares (calculated)
- Trailing-twelve-month FCF$9.11B — FY2025 FCF ($8.39B: $9.60B operating cash flow minus $1.21B capex) plus 1H FY2026 FCF ($0.15B) minus 1H FY2025 FCF (-$0.58B)
- Total debt$31.46B — 10-K FY2025 balance sheet (Dec 31, 2025): $0.59B current + $30.87B long-term
- Cash and equivalents$7.68B — 10-K FY2025 balance sheet
- Net debt$23.79B — calculated
- Discount rate (WACC)9% base case (8%/10%/12% tested)
- Terminal growth rate2.5% — long-run GDP-level assumption
Normalization check: the 3-year average FCF (2023-2025) is $9.20B; FY2025's standalone figure ($8.39B) is -8.8% below that average — within the ±40% threshold, so no adjustment was strictly required. Trailing-twelve-month FCF ($9.11B) was used as the representative figure instead, to correct for first-half seasonality typical of a health insurer's cash flow.
Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's target enterprise value (market cap plus net debt).
Historical CAGR check: 4-yr FCF CAGR (2021→2025) = ($8.39B ÷ $6.04B)^(1/4) − 1 = 8.6%. 4-yr revenue CAGR = ($274.9B ÷ $174.1B)^(1/4) − 1 = 12.1%.
The fine print
- This isn't a fair-value price target — it only shows what the current price already assumes.
- Change the discount rate or the FCF base, and the answer moves somewhat, though the broad conclusion (a very low or negative required growth rate) holds across the range tested — see the sensitivity table above.
- A negative required growth rate doesn't necessarily mean the stock is "cheap" — it may simply reflect that the market has already priced in real risks (PBM rebate regulation, medical cost inflation, large-customer concentration) covered in the snapshot and story pieces above.
- A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
- Any investment decision, and its outcome, is your own responsibility.
Frequently asked questions
What growth rate does CI's stock price assume?
At today's price, Cigna's stock implies roughly -2.8% annual free-cash-flow growth for the next ten years at a 9% discount rate — essentially flat to slightly declining cash flow.
How does that compare to Cigna's actual growth?
Cigna's actual free cash flow grew 8.6% a year over the past 4 years, and revenue grew 12.1% a year over the same span — both far above what the current price requires.
What share price was used for this analysis?
This analysis used $276.08, as of the Aug 31, 2026 close.